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Abstract 
We have established the main post-translational modification of the major exoglucanase of Saccharomyces cerevisiae as the enzyme 
progresses through the secretory pathway. The protein portion of the enzyme accumulated by secl8 cells was about 2 kDa larger than that 
of the secreted enzyme. This precursor (form A) was stable when maintained in the endoplasmic reticulum but was processed to the 
mature form (form B) before the block imposed by the sec7 mutation. Sec7 cells, when incubated at 37°C, accumulated form B first, but 
upon prolonged incubation, form A was preferentially accumulated. When the supply of newly synthesized exoglucanase was prevented 
by the addition of cycloheximide, the accumulated A was transformed into B in the presence of altered Sec7p that still prevented 
secretion. Conversion of A into B was prevented in the double mutant sec7 kex2-1, indicating that Kex2p is central to the in vivo 
processing. Consistent with this, a KEX2 deletion mutant secreted form A exclusively. Conversion of A into B was also prevented in 
sec7 cells by the presence of dinitrophenol, a poison that depletes ATP levels, indicating that processing is dependent upon intracellular 
transport which involves ER ~ Golgi and/or, at least, one intra-Golgi step(s). It follows that this transport step(s) is independent of 
functional Sec7p. 
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1. Introduction 
The primary gene product of the EXG1 gene can be 
differentially glycosylated to give rise to three different 
isoenzymes named exoglucanases Ia and Ib (Exgla and 
Exglb) and Exg325 [1,2]. These isoenzymes are secreted 
into the culture medium via the secretory pathway defined 
by sec mutants [3]. Exgla and ExgIb are constitutively 
produced during the exponential phase of growth and 
account for 10% and 90% respectively of the total activity 
present in culture fluids. Exglb contains two short oligo- 
saccharides attached to asparagine (Asn) residues located 
at positions 165 and 325 of the peptide chain [4,5,1]. The 
inner core of these oligosaccharides share the structure 
reported for the bulk of yeast mannoprotein [6], but the 
a- l ,6 backbone of the outer chain is reduced to one 
mannose and, accordingly, was not affected by the mnn9 
mutation [7]. This mutation prevented, however, synthesis 
of Exgla [8]. Additional experiments indicate that this 
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isoenzyme arises by elongation of the second oligosaccha- 
ride present in Exglb [2]. Exg325 is a minor component 
synthesized at low levels in the late exponential or station- 
ary phases of growth, or when glycosylation is impaired by 
drugs (tunicamycin) or certain mutations (sec53). It con- 
tains only one short oligosaccharide bound to Asn3:5 [1]. 
All these features convert the exoglucanase system in a 
valuable tool for the study of oligosaccharide transfer and 
processing along the yeast secretory pathway. 
Exoglucanase is also a good model for the study of 
protein processing during secretion. Studies from this labo- 
ratory have shown that supematant fluids from protoplast 
lysates of Saccharomyces cerevisiae contained an activity 
which converted a molecular form of exoglucanase (form 
A) into another one (form B). Form B is identical to the 
mature secreted enzyme purified from the culture medium. 
Forms A and B can be separated by ion exchange chro- 
matography since the second behaves significantly more 
acidic than the former [9]. Several observations have led us 
to believe that the Kex2 endoprotease plays a central role 
in the transformation of A into B. First, the above-men- 
tioned transformation was completely inhibited in vitro by 
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either EDTA or leupeptin, two inhibitors of the Kex2. 
Second, a kex2 mutant, deficient in the active protease, 
secreted into the culture medium an A-like form of exoglu- 
canase. Third, sequencing of the amino terminus of the 
A-form of exoglucanase indicated the presence of the 
tetrapeptide, Asn-Lys-Lys-Arg preceding that of the ma- 
ture enzyme [10]. As described, the dipeptide Lys-Arg is 
cleaved at its carboxyl side by the Kex2 protease [11]. In 
these experiments we present evidence indicating that the 
transformation of A into ]3 occurs in vivo after the first 
execution point of secl8 mutation. In addition, it involves 
the cleavage of a larger peptide and requires at least one 
transport step which is independent of a functional Sec7p. 
2. Materials and methods 
2.1. Strains, plasmids, growth conditions and materials 
Saccharomyces cerevisi!ae haploid strains X2180 1A 
( MATa, gal2) and its derivatives HMSF-1 (MATa secl-1), 
HMSF~6 (MATa sec7-1) and HMSF (MATa,-sec18-1) 
were kindly prov-ided by Dr. R. Schekman and have been 
described before [12]. RSY299 (MATa sec7-1 ade2 his3- 
11, -15 leu2-3, -112 trpl-1 ura3-1) was provided by L. 
Ballou. Strains 79 (MATa kex2-1 argl his7 ural) and 80 
(MATa kex2-1 adel ural) were from Yeast Genetic Stock 
i 
Center. BFY 109-1C (MATa kex2A2::URA3 canl-lO0 
I 
ade2-100 his3-11, 15 leu 2-3, 112 trpl-1 ura3-1) was 
kindly provided by L. Ballou. LB-2B (MATa kex2-1 sec7-1 
I 
ade2-100) was obtained by crossing strains RSY299 and 
80. Following dissection of the asci, individual spores 
were first screened for growth at 37°C. Selected tempera- 
ture-sensitive clones were then screened for secretion of 
form A of the enzyme at the permissive temperature 
(24°C) [10]. Yeast cells were maintained in YEPD medium 
(1% yeast extracts, 2% bactopeptone, 5% glucose, 2% 
agar). They were grown in the same liquid medium. For 
the production and purification of external exoglucanase, 
cells were grown in liquid minimal medium [13] with the 
appropriate supplement of growth factors. 
Endo-/3-N-acetylglucosaminidase (endo H) was a gift of 
Dr. Maley. Zymolyase wa:s obtained from Seikagaku Ko- 
gio (Tokyo). Other chemicals were obtained as described 
[3,7,9,14]. 
2.2. 1on exchange chromatography 
For conventional ion exchange chromatography, dia- 
lyzed samples (1-3 ml) in 25 mM acetate buffer (pH 5.2) 
containing NaN 3 were applied to a column (6 X 0.3 or 
9 × 1.2 cm) of DEAE-Bio.-Gel A equilibrated at 4°C with 
the same buffer. The column was washed with two vol- 
umes of the equilibrating buffer and then eluted with 400 
ml of a linear NaC1 gradient (0-0.5 M NaCI in acetate 
buffer) at a flow of 10 or 60 ml /h  (according to the size of 
the column). Fractions of 4 ml were collected. For ion 
exchange chromatography at high pressure (HPLC), 20- 
200 /xl samples in acetate buffer (see above) were applied 
to a Bio-Gel TSK DEAE-5-PW column (75 × 7.5 mm) 
equilibrated in the same buffer. The column was washed 
with 0.2 M NaC1 and then eluted with 200 ml of a linear 
gradient (0.2-0.4 M NaC1) in acetate buffer at a flow rate 
of 0.5 ml/min and a pressure of 4 bars. Fractions of 0.5 
ml were collected. 
2.3. Other methods 
Enzymatic assays were carried out as described by 
Hern~indez et al. [3] using p-nitrophenol-/3-~glucoside 
(p-NPG) as a substrate. Units of activity are expressed in 
/xmol of p-nitrophenol released per hour at 30°C. Determi- 
nation of the activity accumulated by sec mutants, includ- 
ing transformation f cells into protoplasts and separation 
and subsequent fractionation of the internal soluble activity 
has been reported [3,10]. Purification of Exglb, gel filtra- 
tion through Sephacryl S-200, sodium dodecyl sulphate- 
polyacrylamide gel electrophoresis (SDS-PAGE), and 
preparation and purification of antibodies against he pro- 
tein portion of Exg have been described [14]. After elec- 
trophoresis, samples were stained with silver [15]. Im- 
munoblots were performed as reported by Larriba et al. [9]. 
Amino terminal sequence determinations were performed 
as described [8]. Standard eglycosylation reactions (5 mU 
of Endo H and about 15 units of exoglucanase in a final 
volume of 280/zl) were performed in 50/zM citrate-phos- 
phate buffer (pH 5.6), for 5 h in the presence of phenyl- 
methylsulphonylfluoride (PMSF) (1 raM) and pepstatin A
(20 /xM). 
3. Results 
3.1. Analysis of the exoglucanase forms accumulated by 
yeast secretory mutants 
Representative y ast secretory mutants, blocked at dif- 
ferent steps of the yeast secretory pathway, were allowed 
to accumulate exoglucanase for 2 h at the non-permissive 
temperature. At that time, the internal activity was ana- 
lyzed by ion exchange chromatography. As shown in Fig. 
la, secl8, which is blocked at an early step of the pathway 
(fusion of ER-derived vesicles with cis-Golgi cisternae), 
accumulated a form of enzyme much less acidic than secl 
(Fig. lc), which is defective in one of the last steps of that 
pathway (fusion of secretory vesicles with the plasma 
membrane), sec7 (Fig. lb), which is defective at an inter- 
mediate step and exaggerates Golgi-like structures, accu- 
mulated both the less acidic form typical of secl8 (form 
A) and the most acidic one representative of secl (form 
B). 
As shown for the mature secreted enzyme, the internal 
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forms were glycoproteins containing N-glycosidically 
linked carbohydrate, since they bound to a ConA-Sep- 
harose column. Treatment with endo H resulted in the loss 
of this ConA-binding activity. Immunoblot analysis of the 
different forms did not reveal appreciable differences in 
molecular mass [9]. However, following deglycosylation 
with endo H (Fig. ld, lanes 1-5), it was observed that the 
protein moiety of form A from sec18 (lane 1) was about 2 
kDa larger that its counterpart from the secreted enzyme 
(lane 2). Deglycosylated A from sec7 contained two dis- 
tinct and discrete populations of molecules (lane 3). The 
heaviest population co-migrated with deglycosylated A 
from the ER, whereas the lightest one was slightly larger 
than the deglycosylated form B accumulated by the same 
mutant (lane 4). The latter co-migrated with both deglyco- 
sylated B from secl (lane 5) and deglycosylated secreted 
enzyme. It should be noted that the extra peptide present in 
the heaviest A form appears to be larger than the reported 
tetrapeptide present in the enzyme secreted by a kex2 
mutant [10]. At that time we anticipated the existence of an 
additional extra sequence in the form A when present in 
the ER. We have now purified the intact form accumulated 
by sec18 at the restrictive temperature. The protein portion 
of the purified material had the mobility of the immuno- 
reactive material shown in lane ! of Fig. l d. However, 
amino acid sequencing has not been possible since the 
amino terminus was blocked. Nevertheless, the sequence 
of the gene predicts the presence of an extra peptide whose 
sequence is shown in the inset of Fig. l d (form A). We 
have recently confirmed that sequence in a chemically 
modified protein obtained by the combined eletion of the 
dipeptide EE and the mutation of KKR--* GGG (J.P. 
Luna-Arias and G. Larriba, unpublished results). On the 
other hand, the protein portion of the lighter epresentative 
of form A (i.e., the fastest moving band of lane 3 from Fig. 
l d), comigrated with its counterpart from the form A 
purified in a previous report from the culture medium of 
the kex2-1 mutant. The amino terminal sequence of this 
form is also shown in the inset of Fig. ld (Form A'). 
3.2. Accumulation kinetics of forms A and B in the yeast 
secretory mutants 
The internal activity of each of the mutants progres- 
sively increased uring the incubation at 37°C. At the 
indicated times, samples were analyzed by ion exchange 
chromatography. As expected from the results shown in 
Fig. 1 (panels a and c), sec18 and secl only accumulated 
forms A and B respectively during this period. In the case 
of sec7, it was observed that form B started to accumulate 
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Fig. 1. Panels a, b, c: Elution profile of exoglucanase accumulated by secl8 (a), sec7 (b) and secl (c). Cells (A600 of 1.5) were incubated at 37°C in 
YEPD medium (5% glucose) for two hours. Then they were transformed into protoplasts which were lysed in 25 mM acetate buffer (pH 5.2), 
supplemented with 10 mM EDTA. Lysates were homogenized in a glass homogenizer (40 strokes) and centrifuged at 126000 X g for 1 h. High speed 
supernatants were then applied to a BioGel TSK-5-PW column, which was eluted as indicated in Section 2. Panel d: Immunoblot analysis of the forms 
accumulated by representative y ast secretory mutants. Active fractions from the different peaks in panels a, b and c were pooled separately, concentrated 
and deglycosylated with endo H in the presence of 10 mM EDTA. Then they were subjected to immunoblot analysis as follows. Lane 1, peak A from 
secl8 (panel a); lane 2, peak B from secl (panel c); lane 3, peak A from sec7 (panel b); lane 4, peak B from sec7 (panel b); lane 5, control of 
deglycosylated secreted Exg. Inset of panel d: A, sequence of the propeptide predicted by the cloned gene. ~ ,  sequence of the propeptide determined 
chemically from purified form A isolated from the culture medium of a kex2 deletion mutant or accumulated in the ER by secl8 (for more details see the 
text). The arrow indicates the amino terminus of the protein secreted by wild-type. 
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from the beginning of the u'ansfer at the restrictive temper- 
ature, whereas form A was first clearly visible in the 
sample taken after 30 min (Fig. 2). Both forms increased 
during the next 60 min; afterwards, form B stopped grow- 
ing or increased slightly and form A was preferentially 
accumulated (Fig. 2). It should be mentioned that no 
increase in external exoglucanase was observed uring the 
accumulation at 37°C, indicating that secretion was com- 
pletely blocked. Assuming that A is transformed into B 
(see below), the preferential ccumulation of the precursor 
at long incubation times could be attributed to a delay in 
transport caused by either a topological saturation of a 
compartment or depletion of a component involved in 
vesicular transport. In both cases the final result would be 
the accumulation of unprocessed molecules in a previous 
compartment. Alternatively, A and B could share the same 
compartment, and the decrease in the rate of processing 
could be due to the depletion of one component involved 
in the transformation or the accumulation of an inhibitor 
(see below). 
As reported before [3], a large percentage of the activity 
accumulated by these mutants was secreted following 
transfer of the cells to the permissive conditions in the 
presence of cycloheximide. At the indicated times of the 
secretion period (Fig. 3), the internal activity was obtained 
and the levels of forms A and B quantified. In the case of 
seclS, the amount of A decreased at an exponential rate 
and this drop was not paral]eled by a concomitant accumu- 
lation of B which remained at basal levels (Fig. 3a). 
Assuming that A is transformed into B at some point of 
the secretory pathway (see below), this result indicates that 
the rate of exit of B is at least equal to the sum of both the 
rate of arrival of A to the processing compartment and the 
rate of processing itself. That this was the case was also 
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Fig. 2. Accumulation kinetics of forms A and B of exoglucanase by sec7 
cells incubated for different times at the non-permissive t mperature. 
Cells were transformed into protoplasts at 37°C, which were washed, 
lysed and homogenized as indicated in Fig• h Following centrifugation at
126000× g, supernatants were fi'actionated in the DEAE-Bio-Gel col- 
umn and activity included in peaks A (O)  and B (• )  quantified. 
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Fig. 3. Secretion kinetics of forms A (O)  and B (• )  of exoglucanase 
accumulated during 120 min by secl8 (a), sec7 (b) and secl (c) when 
cells were returned to the permissive temperature (24°C) in the presence 
of cycloheximide (100 ~g/ml) .  For details see legends of Figs. l and 2. 
indicated by the observation with the sec7 strain in regard 
to the internal levels of A and B during the secretion 
period (Fig. 3b). Not only did B not increase or remain at 
the initial levels, but it decreased at about the same rate as 
A. In this mutant he rate of decrease of A was much lower 
than in sec18. Since there are no reason to believe that the 
rate of processing should be higher in sec18, the lower 
rate of transformation of A into B in sec7 should be 
attributed to an intrinsic transport problem. It has been 
shown previously that the thermo-reversibility for the se- 
cretion of exoglucanase was much lower for sec7 than for 
sec18 [3]. The rate of secretion of form B accumulated by 
secl was intermediate (Fig. 3c). Regardless of the mutant 
used, only form B was detected in the culture medium, 
suggesting that in sec18 and sec7 form A is transformed 
into form B before being secreted. 
3.3. Transformation of A into B occurs after the exoglu- 
canase leaves the ER and is Kex2-dependent 
In order to follow more directly the transformation f A 
into B, sec7 cells were incubated for 90 min at the 
restrictive temperature• Then, cycloheximide was added to 
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Fig. 4. Stability of the activity accumulated by sec7 cells at 37°C. Cells 
were first incubated at 37°C for 90 min (first incubation). At this time 
(zero time) cycloheximide (100 /~g/ml) was added and the incubation 
continued at the same temperature (second incubation). At different 
times, samples were taken and the internal activity determined in the high 
speed supernatants from protoplast lysates as indicated in Fig. 1. 
inhibit synthesis of new protein and the culture was main- 
tained at the same temperature for an additional period of 
150 min. As shown in Fig. 4, no changes in the activity 
accumulated during the first 90 min were detected uring 
the second incubation period, indicating that the block in 
secretion was present and that intracellular degradation 
was not occurring. In agreement with this, no increase in 
external exoglucanase was observed. When the internal 
activity was analyzed at the times indicated, more than 
60% of accumulated A was transformed into B within the 
first 30 min in the presence of cycloheximide (Fig. 5a-c). 
When the same experiment was carried out with secl8, 
there was no indication of transformation f A into B (Fig. 
5d-f). Fig. 6 summarizes these results. It should be noted 
that the rate of decrease of A during the chase at 37°C in 
sec7 cells was slightly higher than that observed when the 
same cells were transferred to 24°C (see Fig. 3. This is 
probably due to the fact that in the experiment of Fig. 3 the 
cells had been maintained longer (120 min) at 37°C. When 
this period was reduced to 90 min no differences could be 
detected, indicating that the conformational state of Sec7p, 
which is supposed to be temperature-dependent, does not 
influence the rate conversion of A into B. Similarly, an 
increase in the length of the first incubation period of the 
chase experiment (90 to 120 min) slightly decreased the 
rate of processing. 
In order to further support he involvement of Kex2p in 
the transformation f A into B, we analyzed the nature of 
the exoglucanase accumulated by the double mutant sec7 
kex2-1. With this mutant only A was accumulated (Fig. 7). 
These results demonstrate he in vivo transformation of A 
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Fig. 6. Quantification of forms A tiC), O) and B (z~, A) from see7 open 
symbols) and secl8 (closed symbols) during the secretion period, as 
deduced from the results hown in Fig. 5. 
into B and the involvement of the Kex2 protease in this 
conversion. The data also show that the processing oc- 
curred after the first execution point of the secl8 mutation 
and was not prevented by a sec7 mutation that drastically 
blocked a very precise step downstream from the point at 
which Kex2p becomes active. It should be mentioned that 
although the double mutam sec7 kex2-1 only accumulated 
form A, about 20% of the exoglucanase secreted by the 
parent strain kex2-1 into the culture medium was found to 
be in the B form. The amino terminal sequence of this 
material was identical to that of the mature nzyme. We do 
not know whether this mutant was leaky or perhaps has 
another endoprotease(s) with an identical specificity. Such 
an enzyme(s) has been re, ported in yeast [16,17]. More 
importantly, a kex2 mutant, in which the structural gene 
has been deleted (BFY 109-1C), secreted form A exclu- 
sively. However, the different genetic background of both 
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Fig. 7. Analysis of the activity accumulated by the double mutant sec7 
kex2-1 when incubated for 2 h at 37°C. Cells were processed as indicated 
in Fig. 1, and high speed supernatants from protoplast lysates were 
analyzed in the Bio-Gel TSK DEAE-5-PW. 
mutants makes it difficult to discern between the two 
possibilities mentioned above. 
In order to further confirm the role of the Kex2 endo- 
protease in the transformation of A into B, we performed 
additional in vitro studies. In addition to EDTA and leu- 
peptin [10], EGTA and antipain were found to quantita- 
tively inhibit the transformation of form A into form B in 
protoplast lysates from sec7 cells that bad accumulated 
exoglucanase for two hours. The fact that four different 
well characterized inhibitors of Kex2 [11] prevented pro- 
cessing of A into B strongly supports our contention that 
this conversion is exclusively attributable to the action of 
the Kex2 protease. Therefore, EDTA as the sole protease 
inhibitor present in the lysis buffer can effectively prevent 
the non-physiological conversion of Exg upon cell lysis. 
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Fig. 8. Energy dependency of the transformation f A into B. see7 cells 
that were incubated for 90 min at 37°C and exhibited the exoglucanase 
profile shown in panel a, were supplemented with cycloheximide (100 
/~g/ml), divided into two aliquots, centrifuged and resuspended in mini- 
mal medium. One was supplemented with 100 /~M DNP and no glucose 
(b), whereas the other contained 0.5% glucose and no DNP (c). After 90 
additional rain at 37°C, cells were transformed into protoplasts, and the 
internal evels of forms A and B determined as in Fig. 1. 
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By contrast, the in vitro processing of A into B occurred in 
the presence of compounds that do not affect Kex2 pro- 
tease such as PMSF, pepstatin and /3-mercaptoethanol. 
N-ethyl maleimide (NEM), an inhibitor of the intercom- 
partmental protein traffic [18,19], was also ineffective, 
indicating that the in vitro processing was independent of 
fusion of small vesicles that could be present in protoplast 
lysates. The addition of 5 mM Ca 2+ to protoplast lysates 
prepared in 10 mM EDTA reverted the inhibition caused 
by the latter and resulted in a progressive conversion of 
form A into form B (not shown). As observed by Fuller et 
al. [11] Kex2 is a Ca2+-dependent protease. Finally, it 
should be mentioned that the in vitro or the in vivo (see 
Figs. 5 and 8) transformation f A into B did not result in 
an increase in the pNPG hydrolyzing activity of the en- 
zyme. 
3.4. Transformation of A into B involves intracellular 
transport 
As mentioned above, accumulation of A by sec7 cells 
after prolonged incubation at 37°C (Fig. 2) could result 
from a decrease in either the rate of transport or the rate of 
processing itself. If the rate of transport were affected 
only, transformation of A into B would require vesicular 
transport, which is, in turn, dependent on the presence of 
ATP. This nucleotide appears necessary for both budding 
and fusion events of the vesicular transport [20]. In order 
to discern between both possibilities, sec7 cells that had 
accumulated exoglucanase for two hours were incubated in 
the presence of DNP to deplete the ATP levels [21]. Under 
these conditions, no transformation of A into B was ob- 
served during the subsequent incubation period (90 min at 
37°C) in the presence of cycloheximide (Fig. 8a,b). By 
contrast, control cells with normal evels of ATP converted 
more than 90% of A into B when maintained under the 
same conditions (Fig. 8c). We conclude that transforma- 
tion of A into B requires at least a vesicular transport step. 
This event(s) occurred in the presence of altered Sec7p. 
4. Discussion 
In a previous report we have presented preliminary 
evidence on the processing of the major yeast exoglu- 
canase by the Kex2 protease. At that time, our proposal 
was based on the analysis of the amino-terminal sequence 
of the protein (form A) secreted by a kex2 mutant and on 
the nature of the transformation f one form (A) into other 
(B) in protoplast lysates of sec7 cells that had accumulated 
both forms. In the present work, we have extended our in 
vitro studies and provide definitive evidence that transfor- 
mation by the Kex2 protease occurs in vivo after the first 
execution point of secl8 mutation. 
We must first emphasize that conversion of A into B as 
analyzed in ion exchange chromatography, effectively re- 
flects a proteolytic event. The possibility that it arises from 
phosphorylation f Exglb oligosaccharides is discarded by 
the following evidence: (1) form A secreted by a kex2 
mutant co-elutes with form A accumulated by secl8 (Fig. 
7), indicating that addition of phosphate at some step 
through the secretory pathway does not affect the ionic 
behaviour of A; (2) form B secreted by mnn6 mutant, 
which does not add phosphate to its N-oligosaccharides, 
co-elutes with form B from wild type [1]; and (3) deglyco- 
sylated B also elutes more acidic than deglycosylated A 
[10]. 
We have been able to detect in SDS-PAGE the true 
secretory intermediate accumulated in the ER by secl8 
cells. The calculated molecular weight matches that pre- 
dicted by the cloned gene once the signal peptide is 
cleaved [5], confirming our expectation about the size of 
the propeptide [ 10]. 
When accumulated in the ER (secl8), the proenzyme 
was stable, a fact previously described for pro-afactor 
(pelF) [22]. Provided that enough Kex2 protease has been 
synthesized uring the accumulation period, this observa- 
tion indicates that either Kex2p is inactive at this step of 
the pathway (due, perhaps, to lack of free Ca2+), or it 
travels to Golgi in a kind of intermediate vesicles which do 
not contain any of both substrates, p c~ F and exoglucanase. 
Similar arguments have been used to explain the stability 
of p c~ F accumulated in the same location [23]. In contrast 
to other counterparts such as pro-protease A or pro-Kex2 
protease, in which the presence of the propeptide abolishes 
or diminishes the enzymatic activity [24,25], the precursor 
form of exoglucanase appeared to display enzymatic activ- 
ity against pNPG, suggesting that the propeptide may be 
used for purposes other than to maintain the enzyme in a 
cryptic form. As shown for Kex2p, carboxypeptidase Y 
and proteinase A, it could act as a chaperone to guide 
folding of the catalytic domain [25,26,24]. 
Our results indicate that form A accumulated by sec7 
cells was transformed into form B in vivo at 37°C, and that 
transformation required at least one step of vesicular trans- 
port. This step occurred in the presence of a Sec7p alter- 
ation (caused by the temperature) that otherwise prevented 
Golgi exit. These results challenge some current concepts 
concerning the function of SecTp. The SEC7 gene product 
has been suggested to regulate protein transport between 
functional compartments of the Golgi apparatus and be- 
tween the ER and Golgi [27,28]. This proposition was 
primarily based on the observed accumulation of glyco- 
protein intermediates with different degrees of glycosyla- 
tion (invertase, carboxypeptidase Y and p a F) in sec7 cells 
incubated at the restrictive temperature. The presence of 
heterogeneous populations of the three markers was at- 
tributed to an incompletely restrictive defect imposed by 
the altered Sec7p [27]. An alternative, more likely, inter- 
pretation of these observations i that Sec7p is not abso- 
lutely required for intra-Golgi transport but that a single 
block in an intermediate or, most probably, late Golgi 
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cistemae, results in the accumulation of earlier compart- 
ments and, accordingly, earlier intermediates. This situa- 
tion may occur if there is a limit in the size of a compart- 
ment, and the rate of enlargement decreases as the size 
increases. Another possibility is that one or more compo- 
nents necessary for the vectorial transport throughout suc- 
cessive Golgi compartmenl-s are only retrieved from stages 
distal to the step blocked in sec7. Under restrictive condi- 
tions these components would remain bound to the en- 
larged compartment and accumulate there, decreasing their 
concentration i  the cytosol. As a consequence the intra- 
cellular transport would slow down and could even stop. 
The fact that the rate of conversion of A into B during the 
chase period at 37°C was comparable to the rate of de- 
crease of accumulated A during the secretion period at 
24°C favors this second interpretation. Were Sec7p in- 
volved in the transport step(s) we are detecting, then one 
should expect the rate of processing to be higher at 24°C 
than at 37°C. 
The nature of the Golgi compartment in which conver- 
sion of A into B takes place has not been defined by our 
studies but some speculations can be made (Fig. 9). Kex2 
protease appears to be located in a late Golgi compartment 
that also contains SecTp 1130]. One possibility is that, as 
suggested above, form A from the ER reaches first the 
Golgi compartment in which it receives the terminal cz 1,2 
mannose (which is present in practically all ExgIb oligo- 
saccharides [7,29]), and from here it is transported to a late 
Golgi cisternae in which it encounters active Kex2p (path- 
way 1 in Fig. 9). This later compartment should be differ- 
ent from the one in which Kex2 is actively engaged in 
processing substrates since the latter appears to be beyond 
the compartment in which a- l ,3  mannoses are added 
[22,23] and the access to this compartment appears to be 
blocked in sec7 cells [27]. If sec7 cells accumulate only 
Golgi cisternae, transformation of A into B in these cells 
would require only intra-Golgi transport (one or more 
steps) (Fig. 9, pathway 1, continuous line). However, if 
ER-derived vesicles (including or not ER) are also accu- 
mulated in response to the sec7 block, the transformation 
could require, in addition to the intra-Golgi transit, an 
additional (ER to Golgi or ER-derived vesicles to Golgi) 
transport step (Fig. 9, pathway 1, discontinuous line). A 
second possibility is that form A meets active Kex2p in the 
first Golgi cisterna it arrives in (pathway 2 in Fig. 9 ). In 
this case, form A which accumulates in sec7 cells, would 
be located in intermediate vesicles (and perhaps ER). 
Accordingly, conversion of A into B would be independent 
of intra-Golgi transport but dependent on either a fusion 
event (intermediate vesicles with Golgi cisternae) or a 
whole round of vesicular transport (ER--* intermediate 
vesicles --* Golgi cisternae). 
A definitive answer to some of these questions will 
emerge from a detailed characterization of oligosaccha- 
Sect block. ~>~:> 
, y .  . . . . . . . .  , _  . . . . . . . . . . . . . . . . . . . .  . . . - .~  
Kox2p 
ct-l,3 mannosyl 
transferase 
Active Kex2p? 
Terminal 
c~-I,2 mannosyl 
transferase 
chain ( a-1,6 mannosyl 
,,,.. gooOOo 
Fig. 9. Speculative models to explain the intracellular transport and processing of yeast exoglucanase. Pathway 1: Form A arrives to a functional Golgi 
compartment and transformation into B requires at least one intra-Golgi transport step (continuous line). If, as a consequence of the block, earlier 
intermediates are also accumulmed, the conversion of A into B would also involve ER to Golgi transport (discontinuous lines). Pathway 2: Form A 
encounters active Kex2 protease upon arrival in the first functional Golgi compartment, so that conversion of A into B would only need ER to Golgi 
transport. The Golgi cisternae drawn with discontinuous lines represents one or more compartments; in one of them Kex2 becomes active. The sec7 block 
has been placed before the compartment containing the c~- 1,3 mannosyl transferase according to Franzusoff and Schekman [27]. For the sake of simplicity, 
each cisterna has been identified with a unique marker. However, it is likely that different markers coexist in different proportions in more than one 
compartment [31]. 
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rides present in Exg accumulated by sec12 and sec18 as 
well as in forms A and B accumulated by sec7. In order to 
confirm the Sec7p-independent vesicular transport de- 
scribed in this work, we have initiated in vitro transport 
assays using permeabilized cells derived from these mu- 
tants (sec7, sec12 and sec18) as donor compartments and 
cytosolic factors and membrane acceptors [32] derived 
from either sec7 or mutants whose altered products are 
known to participate in ER--* Golgi or intra-Golgi trans- 
port. 
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